Skip to main content
TipRanks
Go Ultimate75% OFF

Paragon Care Limited (PGC) AI Stock Analysis

27 Followers
AU:PGC

Paragon Care Limited

(ASX:PGC)

Select Model
Rating:50Neutral
Price Target:AUD 0.16▲(0.00% Upside)
Action:reiterated
Date:08/27/26

The score is primarily held back by weak financial performance: margins compressed materially and earnings turned negative, with leverage rising and free cash flow still negative. Technicals provide partial support via improving short-term momentum, but the longer-term trend remains weaker. Valuation is constrained by the negative P/E, reflecting current losses and limiting confidence in earnings-based attractiveness.

Positive Factors
Strong Revenue GrowthRevenue growth of 21.7% in 2025 and 33.3% in 2026 indicates expanding commercial activity across the healthcare distribution platform. Sustained top-line momentum would broaden the operating base, support customer reach, and provide a foundation for rebuilding profitability over the next several quarters.
Negative Factors
Severe Margin CompressionThe drop in gross margin from 9.0% to 4.3% and near break-even EBIT margin show that recent revenue growth is not translating efficiently into operating profit. Persistently thin margins leave little buffer for cost pressure, pricing challenges, or unfavorable sales mix.

Paragon Care Limited (PGC) vs. iShares MSCI Australia ETF (EWA)

-60%-40%-20%0%20%40%AU:PGC-45.76%EWA+10.71%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 264.85M
Dividend Yield
―
Average Volume (3M)
446.39K
Price to Earnings (P/E)
-16.1
Beta (1Y)
0.86
Revenue Growth
1.84%
EPS Growth
-178.23%
Country
Australia
Employees
869
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Paragon Care Limited Business Overview & Revenue Model

Company Description

Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary pr...

Paragon Care Limited Financial Statement Overview

Summary

Despite strong recent revenue growth (+21.7% in 2025 and +33.3% in 2026), profitability weakened sharply: gross margin fell from 9.0% to 4.3%, EBIT margin was ~0.2%, and the company moved to a net loss in 2026 (net margin -0.4%). Leverage increased (debt-to-equity 0.93 to 1.31) and free cash flow remained negative in 2026 (-A$1.5m) after a deeply negative 2025, limiting financial flexibility.

Income Statement

38Negative

Balance Sheet

55Neutral

Cash Flow

42Neutral
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue3.68B3.68B3.61B2.97B307.63M237.62M
Gross Profit157.46M157.46M324.00M176.07M51.68M36.58M
EBITDA43.70M43.70M89.81M43.18M37.07M23.96M
Net Income-16.03M-16.03M20.57M8.38M12.80M6.63M
Balance Sheet
Total Assets1.37B1.37B1.23B1.13B448.52M438.44M
Cash, Cash Equivalents and Short-Term Investments23.68M23.68M21.90M19.94M970.00K46.20M
Total Debt388.90M388.90M296.52M251.83M122.14M131.26M
Total Liabilities1.08B1.08B915.04M838.97M196.56M196.31M
Stockholders Equity295.88M295.88M319.00M291.92M18.88M235.82M
Cash Flow
Free Cash Flow-1.49M-1.49M-23.04M25.14M-3.30M14.42M
Operating Cash Flow29.09M29.09M-11.35M44.45M17.75M19.03M
Investing Cash Flow-83.04M-83.04M-16.64M-19.52M-31.75M7.07M
Financing Cash Flow59.42M59.42M28.65M-5.95M-10.00M-11.93M

Paragon Care Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price0.16

Price Trends

50DMA0.15Positive
100DMA0.14Positive
200DMA0.15Positive

Market Momentum

MACD0.00Negative
RSI57.83Neutral
STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Positive. The current price of 0.16 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.15, and above the 200-day MA of 0.15, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 57.83 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PGC.

Paragon Care Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:PGC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:PNVAU:PNV71OutperformAUD 576.85M77.128.45%―12.94%-44.50%
AU:EPNAU:EPN67NeutralAUD 9.73M83.333.34%―121.40%―
AU:SIGAU:SIG61NeutralAUD 33.19B47.0814.34%1.38%――
AU:CMPAU:CMP54NeutralAUD 46.94M209.090.93%―18.54%―
AU:TRJAU:TRJ52NeutralAUD 52.74M-85.00-0.62%―-3.05%86.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:PGCAU:PGC50NeutralAUD 264.85M-16.14-5.34%―1.84%-178.23%

* Healthcare Sector Average

Performance Comparison

-50%0%50%AU:PGCAU:SIGAU:PNVAU:CMPAU:EPNAU:TRJDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:PGC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:PGCParagon Care Limited0.16-0.14-47.54%
AU:SIGSigma Healthcare Ltd2.89-0.02-0.55%
AU:PNVPolynovo Limited0.83-0.29-26.11%
AU:CMPCompumedics Limited0.23-0.09-27.69%
AU:EPNEpsilon Healthcare Limited0.030.004.17%
AU:TRJTrajan Group Holdings Ltd0.34-0.31-46.92%

Paragon Care Limited Corporate Events

Paragon Care shareholders carry three resolutions at 2026 AGM

Nov 18, 2026

At its 2026 Annual General Meeting on 18 November 2026, Paragon Care shareholders carried resolutions adopting the remuneration report, re-electing David Collins as a director and appointing the auditor. The remuneration report received 93.40% of vot...

ParagonCare reports 2026 integration completion, acquisitions and buy-back activity

Nov 18, 2026

ParagonCare said its 2026 financial year included completion of its 3-2-1 integration strategy, achievement of sales, EBITDA and net-debt guidance targets, six acquisitions across Asia and Australia/New Zealand, leadership transition completion, and...

Paragon Care Reports Lapse of 4.6 Million Performance Rights

Oct 20, 2026

Paragon Care Limited has disclosed that 4,590,505 performance rights with the ASX security code PGCAJ have lapsed. The lapse occurred because the conditional rights to these securities were not, or could no longer be, satisfied under the terms of the...

Paragon Care Plans Auditor Shift from EY to KPMG After Tender Review

Oct 2, 2026

Paragon Care has selected KPMG as its preferred external auditor following a competitive tender, with the appointment contingent on ASIC consent to Ernst & Young’s resignation and shareholder approval under the Corporations Act. The proposed change w...

Paragon Care Sets Out 2026 Governance and Diversity Framework

Sep 22, 2026

Paragon Care Limited has released its 2026 Corporate Governance Statement, outlining how its Board oversees strategy, risk and compliance across the Group in line with ASX Corporate Governance Council guidelines. The company details a formal Board Ch...

Paragon Care Files Updated Corporate Governance Statement with ASX

Sep 22, 2026

Paragon Care Limited has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming it is available on the company’s website and current as of 23 September 2026. The accompanying Appendix 4G outlines that Paragon Ca...

Paragon Care Confirms FY26 Results With Unqualified Audit Opinion

Sep 22, 2026

Paragon Care Limited has released its audited financial results for the year ended 30 June 2026, confirming that profit after tax, comprehensive income and key balance sheet metrics are unchanged from the preliminary figures lodged in August. The com...

Paragon Care Launches On‑Market Share Buy‑Back of PGC Shares

Sep 15, 2026

Paragon Care Limited has notified the market of an on‑market share buy‑back of its ordinary fully paid shares, traded under the ASX code PGC. The announcement, lodged as a new notice with the Australian Securities Exchange, confirms the company’s int...

Paragon Care launches employee share purchases and $10.8m on-market buy-back

Sep 15, 2026

Paragon Care has directed its Employee Share Trust to purchase up to 23,900,401 ordinary shares on market to satisfy future vesting and grants under the company’s Employee Incentive Plan, with acquisitions governed by price caps, ASX notifications an...

Paragon Care Sets Date and Director Nomination Deadline for 2026 AGM

Aug 28, 2026

Paragon Care Limited has scheduled its 2026 Annual General Meeting for 1.00pm AEDT on 18 November 2026, with the meeting details to be set out in a notice to shareholders and the ASX in October. The company has also set 7 October 2026 as the deadline...

Paragon Care Corrects Typographical Errors in Preliminary Final Report

Aug 26, 2026

Paragon Care Limited, an Australian-listed healthcare supplier, provides a wide range of medical equipment, devices, consumables, pharmaceuticals and complementary healthcare products. It also manufactures blood bank diagnostic reagents, with operati...

Paragon Care Releases FY26 Results and Highlights Cultural Acknowledgement

Aug 26, 2026

Paragon Care Limited has released its financial results for the year ended 30 June 2026 and provided an investor presentation outlining its FY26 performance. While detailed financial metrics are not disclosed in the text provided, the release signals...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026